Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 1/20 | 0.33 |
| ▸ | HTR6 | P50406 | 3/20 | 0.33 |
| ▸ | ACHE | P22303 | 2/20 | 0.33 |
| ▸ | BCHE | P06276 | 1/20 | 0.33 |
| ▸ | GPR3 | P46089 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | NOS2 | P35228 | 1/20 | 0.31 |
| ▸ | HTR5A | P47898 | 1/20 | 0.30 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.30 |
| ▸ | HTR1A | P08908 | 1/20 | 0.30 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.30 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
| ▸ | DRD1 | P21728 | 1/20 | 0.30 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.30 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.30 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.30 |
| ▸ | DRD3 | P35462 | 1/20 | 0.30 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.30 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6129625 | 0.87 | HTR6 (0.39) | HTR6ACHEBCHEGPR3HTR2A | |
| SCHEMBL5702854 | 0.86 | HTR6 (0.36) | HTR6ACHEBCHEHTR5A | |
| SCHEMBL6345275 | 0.75 | ACHE (0.35) | HTR6ACHEBCHEGPR3HTR2A | |
| SCHEMBL8857527 | 0.73 | GPR3 (0.38) | ACHEBCHEGPR3HTR2ACHRM2 | |
| SCHEMBL7624281 | 0.73 | HTR6 (0.47) | HTR6ACHEBCHEGPR3HTR2A | |
| SCHEMBL7542082 | 0.73 | GPR3 (0.33) | GPR3 | |
| SCHEMBL29979921 | 0.73 | GPR3 (0.33) | GPR3 | |
| SCHEMBL6355109 | 0.73 | HTR6 (0.44) | HTR6ACHEBCHEGPR3HTR2A | |
| Hydrochloric Acid SCHEMBL2289539 | 0.72 | HTR6 (0.33) | HTR6 | |
| SCHEMBL9699259 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1066226-B1 | SYNTHESIS AND ISOMERIZATION OF 1,2-BIS (INDENYL) ETHANES | BOULDER SCIENT CO (US) | 2007-08-29 | — | — | EP | claimed |
| EP-1066226-A4 | SYNTHESIS AND ISOMERIZATION OF 1,2-BIS (INDENYL) ETHANES | BOULDER SCIENT CO (US) | 2005-03-09 | — | — | EP | claimed |
| EP-1066226-A1 | SYNTHESIS AND ISOMERIZATION OF 1,2-BIS (INDENYL) ETHANES | BOULDER SCIENTIFIC COMPANY (US) | 2001-01-10 | — | — | EP | claimed |
| WO-2000043331-A2 | SYNTHESIS AND ISOMERIZATION OF 1,2-BIS (INDENYL) ETHANES | BOULDER SCIENTIFIC COMPANY (US) | 2000-07-27 | — | — | WO | claimed |
| EP-1066226-B1 | SYNTHESIS AND ISOMERIZATION OF 1,2-BIS (INDENYL) ETHANES | BOULDER SCIENT CO (US) | 2007-08-29 | — | — | EP | disclosed |
| US-6441258-B1 | ISOMERIZING KINETIC EBI TO THERMODYNAMIC EBI AND ISOMERIZING MESO TMS-EBI TO RACEMIC TMS-EBI; PREPARATION OF A GROUP IV METAL METALLOCENE OLEFIN POLYMERIZATION CATALYST. | BOULDER SCIENTIFIC COMPANY | 2002-08-27 | — | — | US | disclosed |
| US-20020045789-A1 | Synthesis and isomerization of 1,2-bis (indenyl) ethanes | BOULDER SCIENTIFIC COMPANY | 2002-04-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020045789-A1 | Synthesis and isomerization of 1,2-bis (indenyl) ethanes | RAC1, RABGGTB, GDI1 | JAK2 4239/4885HTR6 247/4885ACHE 1405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.